With the RSV season officially underway in South Africa, experts are urging healthcare providers to prepare for an influx of ...
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...
A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.
Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...
Starting this spring, the Respiratory Syncytial Virus (RSV) vaccine will be available to adults aged 60 years and older residing in congregate living facilities, such as long-term care homes and ...
The United Kingdom’s Health Security Agency (HSA) yesterday published it first annual report on infectious disease trends, ...
In primary care settings, the burden of RSV on young children and their guardians often varied between the countries of ...
Hospitalization rates from respiratory syncytial virus (RSV) infection rose with age. Also, hospitalizations were more likely among nursing home residents and older adults with other health issues, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results